In this work, we demonstrated that two known drugs used for treating breast cancer (tucatinib) or lung cancer (capmatinib) might have a dual function and simultaneously inhibit enzymes necessary for the survival and metastasis of these types of cancer, including LDH-B and tyrosine kinase receptors. Here, LDHB is linked to lung cancer.